Clinical Trials
Our laboratory has participated in ≥10 clinical trials (including several for Branhamella and Haemophilus influenzae) since 1988. The below is a list of the NTM trials since 1990.

Trial Title: An Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
Purpose: To determine safety and efficacy of clarithromycin in the treatment of patients with nontuberculous mycobacterial infections (NTM).
Sponsor: Abbott Laboratories
Trial #: 263

Trial Title: Azithromycin in Treatment of Mycobacterium avium Complex (MAC) Lung Disease
Purpose: To determine the safety and efficacy of azithromycin in the treatment of MAC lung disease.
Sponsor: Pfizer Laboratories
Trial #: 340

Trial Title: Open, Non-comparative Trial of Multidrug Regimens Containing Azithromycin and Rifabutin Administered Three Times per Week for the Treatment of M. avium Complex (MAC) Lung Disease
Purpose: To determine safety and efficacy of multidrug regimens containing azithromycin and rifabutin administered three times per week for the treatment of MAC lung disease.
Sponsor: Pfizer Laboratories
Trial #: 426

Trial Title: Open, noncomparative trial of multidrug regimens containing clarithromycin and rifabutin administered three times per week for the treatment of Mycobacterium avium complex (MAC) lung disease or other Nontuberculous Mycobacteria (NTM).
Purpose: To determine safety and efficacy of a multi-drug regimen of clarithromycin, rifampin/rifabutin, and ethambutol given 3 times weekly for the treatment of lung infections with Mycobacterium avium complex (MAC) or other nontuberculous mycobacteria (NTM).
Sponsor: Abbott Laboratories
Trial #: 447

Trial Title: Clinical Efficacy of Rifabutin (formerly Ansamycin LM427 in the Treatment of Serious and Life Threatening Infections due to Mycobacterium avium Complex, or Drug Resistant Mycobacterium tuberculosis, or other Drug Resistant Mycobacterium sp.
Purpose: To assess the clinical efficacy of rifabutin in the treatment of serious infections due to drug resistant Mycobacterium sp.
Sponsor: Pharmacia
Trial #: 72

Trial Title: Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (especially M. abscessus).
Purpose: To determine the safety and efficacy of tigecycline (GAR-936) in the treatment of serious infection due to drug resistant rapidly growing mycobacteria (especially M. abscessus).
Sponsor: Wyeth Research
Trial #: 660

Trial Title: Durable Culture Conversion with Amikacin Liposome Inhalation Suspension for Mycobacterium avium complex Lung Disease
Purpose: To assess the durability of sustained conversion in treatment of refractory MAC lung disease patients and to determine if any safety issues were associated with amikacin liposome inhalation suspension. 
Sponsor: Insmed
Trial #: INS212

Trial Title: Safety and Tolerability of Amikacin Liposome Inhalation Suspension in Treatment Refractory M. avium Complex Lung Disease: A 12 Month Open Label Extension Study
Purpose: To assess the safety, tolerability and clinical efficacy of amikacin liposome inhalation suspension in the treatment of Mycobacterium avium complex lung disease.
Sponsor: Insmed
Trial #: INS312